US 12,226,407 B2
Aerosol pirfenidone and pyridone analog compounds and uses thereof
Mark William Surber, San Diego, CA (US)
Assigned to AVALYN PHARMA INC., Cambridge, MA (US)
Filed by AVALYN PHARMA INC., Seattle, WA (US)
Filed on Jan. 5, 2023, as Appl. No. 18/093,774.
Application 18/093,774 is a continuation of application No. 16/953,144, filed on Nov. 19, 2020, granted, now 11,559,520.
Application 16/953,144 is a continuation of application No. 16/922,958, filed on Jul. 7, 2020, granted, now 11,452,718, issued on Sep. 27, 2022.
Application 16/922,958 is a continuation of application No. 16/167,337, filed on Oct. 22, 2018, abandoned.
Application 16/167,337 is a continuation of application No. 13/950,110, filed on Jul. 24, 2013, granted, now 10,105,356, issued on Oct. 23, 2018.
Claims priority of provisional application 61/824,818, filed on May 17, 2013.
Claims priority of provisional application 61/756,983, filed on Jan. 25, 2013.
Claims priority of provisional application 61/675,286, filed on Jul. 24, 2012.
Prior Publication US 2023/0149375 A1, May 18, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/4418 (2006.01); A61K 9/00 (2006.01); A61M 15/00 (2006.01)
CPC A61K 31/4418 (2013.01) [A61K 9/0073 (2013.01); A61K 9/0078 (2013.01); A61M 15/009 (2013.01); A61M 2202/064 (2013.01)] 14 Claims
 
1. A unit dose of an aqueous solution for delivery by a liquid nebulizer for the daily treatment of interstitial lung disease in an adult human comprising: a respirable delivered dose comprising water and pirfenidone at a concentration from about 5.0 mg/mL to about 20 mg/mL, the aqueous solution having an osmolality of from about 50 mOsmol/kg to about 2000 mOsmol/kg, wherein the respirable delivered dose to lungs of the adult human per day is less than 1.933 mg/kg/day of pirfenidone to reduce a decline in forced vital capacity (FVC) in the lung of the adult human.